Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and sirolimus

cyc 202 has been researched along with sirolimus in 9 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(sirolimus)		Trials
(sirolimus)		Recent Studies (post-2010) (sirolimus)
979739320,7112,36811,516

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)sirolimus (IC50)
Bile salt export pumpHomo sapiens (human)10
ATP-dependent translocase ABCB1Homo sapiens (human)1.25
Cytochrome P450 3A4Homo sapiens (human)2
Cytochrome P450 2C9 Homo sapiens (human)2
Peptidyl-prolyl cis-trans isomerase FKBP1AMus musculus (house mouse)0.001
Cytochrome P450 2C19Homo sapiens (human)4
Serine/threonine-protein kinase mTORHomo sapiens (human)0.0897
Peptidyl-prolyl cis-trans isomerase FKBP1AHomo sapiens (human)0.0042
Regulatory-associated protein of mTORHomo sapiens (human)0.225
Target of rapamycin complex subunit LST8Homo sapiens (human)0.225
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.9
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)1.1

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Coombes, JD; Liddle, C; Mreich, E; Rangan, GK1
Beales, PL; Tobin, JL1
Chowdhury, R; Igarashi, P; Patel, V1
Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M1
Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A1

Reviews

1 review(s) available for cyc 202 and sirolimus

ArticleYear
Advances in the pathogenesis and treatment of polycystic kidney disease.
    Current opinion in nephrology and hypertension, 2009, Volume: 18, Issue:2

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Polarity; Cilia; Humans; Kinesins; Octreotide; Polycystic Kidney Diseases; Purines; Roscovitine; Sirolimus; TRPP Cation Channels

2009

Other Studies

8 other study(ies) available for cyc 202 and sirolimus

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy.
    Kidney international, 2005, Volume: 68, Issue:6

    Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Division; Cyclin D1; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cytoplasm; Epithelial Cells; Female; Growth Inhibitors; Immunosuppressive Agents; Kidney Cortex; Kidney Tubules; Monocytes; Proteinuria; Purines; Rats; Rats, Wistar; Roscovitine; Serum Albumin, Bovine; Sirolimus

2005
Restoration of renal function in zebrafish models of ciliopathies.
    Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:11

    Topics: Animals; Antineoplastic Agents; Bardet-Biedl Syndrome; Cilia; Disease Models, Animal; Immunosuppressive Agents; Kidney; Polycystic Kidney Diseases; Purines; Recovery of Function; Roscovitine; Sirolimus; Zebrafish

2008
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
    PLoS genetics, 2012, Volume: 8, Issue:3

    Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2012
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
    BMC pharmacology & toxicology, 2013, Jun-15, Volume: 14

    Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases

2013